Abstract 242: Healthcare Resource Utilization and Costs among Patients with Non-Valvular Atrial Fibrillation using Dabigatran or Warfarin For Stroke Prevention [Session Title: Poster Session II]

Conclusions: Although newly diagnosed, newly treated NVAF patients initiated on dabigatran had higher pharmacy costs than those on warfarin, the total healthcare costs were similar between the two cohorts. In addition, fewer office visits were observed in the dabigatran cohort.

Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Fu, A.-C., Jain, R., Sander, S. D., Lim, J., Jain, G., Yu, Y., Tan, H. Tags: Session Title: Poster Session II Source Type: research